Computational Design of Viral Capsid-Like Nanoparticles for Antigen Display
By Dr. Zubair Khalid, DVM, MS, PhD ·
Key Takeaways
- Viral capsid-like nanoparticles (CLNs) are engineered protein cages that enhance antigen immunogenicity by presenting antigens in a repetitive, ordered array, significantly improving B cell responses compared to soluble antigens.
- Computational design is crucial for CLN development, involving scaffold selection (e.g., bacteriophage MS2, CCMV, HBV core, CPV, FMDV CPs), identification of solvent-exposed insertion sites on surface loops, and optimization of antigen-linker geometry using molecular dynamics simulations.
- The valency and spatial arrangement of displayed antigens on CLNs are dictated by the capsid's symmetry (e.g., icosahedral T-numbers) and the number of insertion sites per capsid protein, influencing B cell receptor cross-linking and immune response magnitude.
- Stability engineering, including thermal and pH stability, is critical for CLN vaccine platforms, achieved through computational prediction of stabilizing mutations (e.g., using Rosetta) and disulfide bond engineering.
- CLNs have demonstrated efficacy in veterinary applications, such as inducing protective immunity against avian influenza and reducing viremia in pigs infected with PRRSV, highlighting their potential for diverse pathogen targets.
- Challenges in CLN vaccine development include mitigating immunodominance of the capsid scaffold and optimizing antigen size for assembly, with ongoing research focused on universal platforms and scalable production methods.
Introduction
The development of subunit vaccines for veterinary applications has been constrained by the limited immunogenicity of soluble recombinant antigens. Antigens presented in a repetitive, ordered array on a nanoparticle scaffold elicit substantially stronger B cell responses than their monomeric counterparts [<a href="#ref-1">1</a>]. Viral capsid-like nanoparticles (CLNs) are self-assembling protein cages derived from viral structural proteins that retain the ability to form icosahedral or octahedral shells but lack genetic material [<a href="#ref-2">2</a>]. These particles provide a platform for the multivalent display of heterologous antigens on their exterior surface, mimicking the repetitive geometry of native virions [<a href="#ref-3">3</a>]. Computational design methods have become essential for engineering CLNs with defined symmetry, controlled valency, and enhanced thermostability [<a href="#ref-4">4</a>].
This article reviews the biophysical principles governing CLN self-assembly, the computational algorithms used to design antigen display interfaces, and the stability engineering strategies that enable these particles to function as vaccine platforms in veterinary species.
Biophysical Principles of Capsid Self-Assembly
Viral capsids are protein shells that enclose the viral genome. The capsid is composed of multiple copies of one or more capsid proteins (CPs) that assemble into a closed shell with icosahedral symmetry [<a href="#ref-5">5</a>]. Icosahedral symmetry is the most common architecture among spherical viruses and is characterized by 60 identical asymmetric units arranged with 5-fold, 3-fold, and 2-fold rotational symmetry axes [<a href="#ref-6">6</a>]. The triangulation number (T-number) describes the number of CP copies per asymmetric unit; a T=1 capsid contains 60 CP copies, while a T=3 capsid contains 180 copies [<a href="#ref-7">7</a>].
The self-assembly of CPs into a capsid is driven by non-covalent interactions including hydrophobic contacts, hydrogen bonds, and electrostatic interactions at subunit interfaces [<a href="#ref-8">8</a>]. The free energy of assembly must be sufficiently negative to overcome the entropic penalty of ordering many subunits into a closed shell [<a href="#ref-9">9</a>]. Computational models of capsid assembly have been developed using coarse-grained molecular dynamics and Brownian dynamics simulations to predict assembly pathways and identify critical nucleation sites [<a href="#ref-10">10</a>].
For CLN design, the CP must be modified to incorporate heterologous antigen sequences while preserving the ability to assemble into a cage of defined symmetry [<a href="#ref-11">11</a>]. The insertion site must be solvent-exposed, structurally permissive, and located at a position that does not disrupt inter-subunit contacts [<a href="#ref-12">12</a>]. Computational screening of insertion sites is performed using structural alignment of the target CP with homologous proteins of known structure [<a href="#ref-13">13</a>].
Computational Design of Antigen Display Interfaces
The design of a CLN for antigen display requires the selection of an appropriate CP scaffold, the identification of permissible insertion sites, and the optimization of the antigen-CP linker geometry [<a href="#ref-14">14</a>]. Several viral CPs have been used as scaffolds for CLN design, including the CP of bacteriophage MS2, the CP of cowpea chlorotic mottle virus (CCMV), and the CP of hepatitis B virus (HBV) core protein [<a href="#ref-15">15</a>]. For veterinary applications, CPs derived from animal viruses such as the CP of canine parvovirus (CPV) or the CP of foot-and-mouth disease virus (FMDV) have been explored [<a href="#ref-16">16</a>].
The computational workflow for CLN design typically proceeds through the following stages:
- Scaffold selection: The CP is chosen based on its known atomic structure, its ability to assemble into a monodisperse population of particles, and its tolerance to genetic fusion at specific surface loops [<a href="#ref-17">17</a>].
- Insertion site identification: Surface-exposed loops are identified using solvent accessibility calculations performed on the CP crystal structure or cryo-electron microscopy (cryo-EM) reconstruction [<a href="#ref-18">18</a>]. Loops with high B-factors and low sequence conservation are preferred as they are more likely to tolerate insertion [<a href="#ref-19">19</a>].
- Linker design: The antigen is connected to the CP via a flexible linker peptide, typically composed of glycine and serine residues [<a href="#ref-20">20</a>]. The linker length is optimized using molecular dynamics simulations to ensure that the antigen does not sterically clash with neighboring subunits [<a href="#ref-21">21</a>].
- Symmetry modeling: The designed CP-antigen fusion is docked into the icosahedral asymmetric unit using symmetry constraints derived from the parent capsid [<a href="#ref-22">22</a>]. The resulting model is evaluated for steric clashes and inter-subunit contacts using energy minimization [<a href="#ref-23">23</a>].
- Stability prediction: The thermodynamic stability of the designed CLN is predicted using computational tools such as FoldX or Rosetta [<a href="#ref-24">24</a>]. Mutations that destabilize the CP core or disrupt inter-subunit interfaces are rejected [<a href="#ref-25">25</a>].
flowchart TD
A["Select CP scaffold"] --> B["Identify surface loops"]
B --> C["Calculate solvent accessibility"]
C --> D["Select insertion site"]
D --> E["Design linker sequence"]
E --> F["Dock antigen into CP structure"]
F --> G["Apply icosahedral symmetry"]
G --> H["Evaluate steric clashes"]
H --> I["Energy minimization"]
I --> J["Predict stability with FoldX/Rosetta"]
J --> K{"Stable?"}
K -->|"Yes"| L["Express and purify CLN"]
K -->|"No"| D
L --> M["Characterize by SEC and cryo-EM"]
M --> N["Assess antigenicity by ELISA"]Symmetry Constraints and Valency Control
The valency of antigen display on a CLN is determined by the T-number of the capsid and the number of insertion sites per CP [<a href="#ref-26">26</a>]. For a T=1 capsid with 60 CP copies, a single insertion site per CP yields a valency of 60 [<a href="#ref-27">27</a>]. For a T=3 capsid with 180 CP copies, the valency can be 180 if all CPs are modified, or lower if only a subset of CPs carry the antigen [<a href="#ref-28">28</a>].
The spatial arrangement of antigens on the CLN surface is constrained by the symmetry of the capsid [<a href="#ref-29">29</a>]. Antigens displayed at 5-fold symmetry axes are clustered in pentameric rings, while those at 3-fold axes form trimeric clusters [<a href="#ref-30">30</a>]. The distance between adjacent antigens affects the avidity of B cell receptor cross-linking and the magnitude of the antibody response [<a href="#ref-31">31</a>]. Computational modeling of antigen spacing is performed using rigid-body docking and distance geometry calculations [<a href="#ref-32">32</a>].
For some applications, it is desirable to display multiple different antigens on the same CLN to induce a broad immune response [<a href="#ref-33">33</a>]. This can be achieved by co-expressing two or more CP-antigen fusions that co-assemble into mosaic particles [<a href="#ref-34">34</a>]. The stoichiometry of each antigen in the mosaic particle can be controlled by adjusting the ratio of expression plasmids or by using split-protein complementation systems [<a href="#ref-35">35</a>].
Stability Engineering of Capsid-Like Nanoparticles
The stability of CLNs is critical for their use as vaccine platforms, as particles must remain intact during purification, formulation, and storage [<a href="#ref-36">36</a>]. Thermal stability is assessed by differential scanning fluorimetry (DSF) or by measuring the melting temperature (Tm) using circular dichroism spectroscopy [<a href="#ref-37">37</a>]. Computational stability engineering aims to increase the Tm of CLNs by introducing mutations that strengthen inter-subunit contacts or improve the packing of hydrophobic cores [<a href="#ref-38">38</a>].
Rosetta-based design protocols have been used to predict stabilizing mutations in viral CPs [<a href="#ref-39">39</a>]. The protocol involves calculating the change in folding free energy (Delta Delta G) upon mutation and selecting mutations that are predicted to be stabilizing [<a href="#ref-40">40</a>]. Disulfide bond engineering is another strategy for increasing CLN stability; computational tools such as Disulfide by Design are used to identify residue pairs with suitable geometry for disulfide formation [<a href="#ref-41">41</a>].
The pH stability of CLNs is also important, particularly for oral or intranasal vaccine delivery where particles encounter acidic environments [<a href="#ref-42">42</a>]. Computational pKa calculations are used to identify ionizable residues that may become protonated at low pH and cause capsid disassembly [<a href="#ref-43">43</a>]. Mutating these residues to neutral amino acids can improve acid stability [<a href="#ref-44">44</a>].
Computational Tools for CLN Design
Several computational tools and webservers are available for CLN design. The Rosetta macromolecular modeling suite includes protocols for symmetric protein docking, interface design, and stability prediction [<a href="#ref-45">45</a>]. The VIPERdb database provides structural information on icosahedral virus capsids, including symmetry axes and residue-level contact maps [<a href="#ref-46">46</a>]. The Capsid Designer tool, developed for the design of chimeric virus-like particles, allows users to select insertion sites and model antigen-CP fusions [<a href="#ref-47">47</a>].
Molecular dynamics simulations using GROMACS or NAMD are used to assess the conformational dynamics of designed CLNs [<a href="#ref-48">48</a>]. Simulations are typically run for 100-500 ns to evaluate the stability of the antigen-CP linker and the overall particle integrity [<a href="#ref-49">49</a>]. Coarse-grained simulations using the Martini force field are used to study assembly pathways and to predict the effect of mutations on assembly efficiency [<a href="#ref-50">50</a>].
Veterinary Applications and Case Studies
CLNs have been evaluated as vaccine platforms for several veterinary pathogens. For avian influenza virus, the hemagglutinin (HA) globular head domain has been displayed on the surface of CLNs derived from the CP of bacteriophage AP205 [<a href="#ref-51">51</a>]. Vaccination of chickens with these CLNs induced hemagglutination-inhibiting antibodies and protected against challenge with highly pathogenic avian influenza H5N1 [<a href="#ref-52">52</a>]. This approach is relevant to the control of Highly Pathogenic Avian Influenza (H5N1) in Poultry and Wild Birds: Clinical Signs, Transmission Dynamics, and Surveillance Maps.
For porcine reproductive and respiratory syndrome virus (PRRSV), the GP5 ectodomain has been displayed on CLNs derived from the CP of the MS2 bacteriophage [<a href="#ref-53">53</a>]. Vaccination of pigs with these CLNs reduced viremia and lung pathology following challenge [<a href="#ref-54">54</a>]. This work is discussed in the article Porcine Reproductive and Respiratory Syndrome: Genomic Surveillance and Vaccine Strategies Using Bioinformatics.
For canine parvovirus, the VP2 protein has been used as a scaffold for the display of heterologous epitopes from other canine pathogens [<a href="#ref-55">55</a>]. The VP2 protein naturally assembles into T=1 capsids, and insertion sites at the VP2 surface loops have been identified using computational modeling [<a href="#ref-56">56</a>].
Challenges and Future Directions
Despite the success of CLN-based vaccines in preclinical studies, several challenges remain. The immunodominance of the CP scaffold can suppress the antibody response to the displayed antigen [<a href="#ref-57">57</a>]. Computational strategies to reduce CP immunogenicity include the removal of dominant B cell epitopes from the CP surface [<a href="#ref-58">58</a>]. The size of the displayed antigen is also a constraint; large antigens can sterically hinder assembly or reduce particle yield [<a href="#ref-59">59</a>]. Computational modeling of antigen-CP fusions is used to predict the maximum permissible antigen size for a given insertion site [<a href="#ref-60">60</a>].
The production of CLNs at commercial scale requires high-yield expression systems and robust purification protocols [<a href="#ref-61">61</a>]. Computational optimization of codon usage and mRNA secondary structure can improve expression yields in bacterial or insect cell systems [<a href="#ref-62">62</a>]. The development of universal CLN platforms that can accommodate many antigens without redesign of the CP scaffold is an active area of research [<a href="#ref-63">63</a>].
Conclusion
Computational design has become an indispensable tool for engineering viral capsid-like nanoparticles for antigen display. The integration of structural biology, molecular dynamics, and protein design algorithms enables the rational construction of multivalent vaccine platforms with defined symmetry, controlled valency, and enhanced stability. These platforms hold significant promise for the development of effective vaccines against veterinary pathogens, particularly those for which traditional vaccine approaches have been inadequate.